WET MACULAR DEGENERATION
Clinical trials for WET MACULAR DEGENERATION explained in plain language.
Never miss a new study
Get alerted when new WET MACULAR DEGENERATION trials appear
Sign up with your email to follow new studies for WET MACULAR DEGENERATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New eye drug tiespectus takes on aflibercept in major wet AMD trial
Disease control Recruiting nowThis study tests a new medicine called tiespectus (EYE201) for wet age-related macular degeneration, a leading cause of vision loss. About 960 people will receive either tiespectus or the standard treatment aflibercept via eye injections. The goal is to see if tiespectus can impr…
Matched conditions: WET MACULAR DEGENERATION
Phase: PHASE2, PHASE3 • Sponsor: EyeBiotech Ltd. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New eye injection could change treatment for wet AMD
Disease control Recruiting nowThis study tests a new drug called tiespectus (MK-8748) against the current standard treatment, aflibercept, for people with wet age-related macular degeneration (AMD). About 960 participants will receive injections into the eye and be followed for a year to see if tiespectus can…
Matched conditions: WET MACULAR DEGENERATION
Phase: PHASE2, PHASE3 • Sponsor: EyeBiotech Ltd. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC